House Oversight — Estate records
- Pages
- 6
- Text
- Searchable
Text as released
Machine-read from the scan. Names, dates and numbers can be misread — check anything you rely on against the original page.
From: jeffrey E. [jeevacation@gmail.com] Sent: 7/24/2015 8:47:39 PM To: Sultan Bin Sulayem Subject: Re: FDA Approved a Potent and Pricey Cholesterol lowering drug today yes, it requires a shot, its not a pill and so far no long term effects known On Fri, Jul 24, 2015 at 4:37 PM, Sultan Bin Sulayem < Have you heard of this colestrol Jul 24, 2015 @ 3:23 PM 1,169 views _ wrote: The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot Matthew Herper, Forbes Staff I cover science and medicine, and believe this is biology's century. • Follow on Forbes f1970) Full Bio Recent Posts • Popular Posts I believe this is biology's century. I've covered science and medicine for Forbes from the Human Genome Project through Vioxx to the blossoming DNA technology changing the world today. Email me, follow me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page. Loading... Loading... The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or stroke is not being adequately controlled by existing drugs called statins. It might be a big step in the battle against heart disease — and the approval is a triumph for Regeneron Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost HOUSE OVERSIGHT 026362 down the line. "Obviously, the class is one of the biggest developments in cardiology in the last decade, that will allow us to treat patients who have been extremely difficult to treat with high levels of LDL cholesterol," says Steven Nissen, chairman of cardiology at the Cleveland Clinic. "It's very promising." But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant pharmacy benefits manager."If these […]